Accurate estimates of breast and ovarian cancer penetrance in BRCA1/2 mutation carriers are crucial in genetic counseling. Estimation is difficult because of the low frequency of mutated alleles and the oftenuncertain mechanisms of family ascertainment. We estimated the penetrances of breast and ovarian cancers in carriers of BRCA1/2 mutations by maximizing the retrospective likelihood of the genetic model, given the observed test results, in 568 Italian families screened for germline mutations. The software BRCAPRO was used as a probability calculation tool in a Markov Chain Monte Carlo approach. Breast cancer penetrances were 27% (95% CI 20-34%) at age 50 years and 39% (27 -52%) at age 70 in BRCA1 carriers, and 26% (0.18 -0.34%) at age 50 and 44% (29 -58%) at age 70 in BRCA2 carriers, and ovarian cancer penetrances were 14% (7-22%) at age 50 and 43% (21-66%) at age 70 in BRCA1 carriers and 3% (0 -7%) at age 50 and 15% (4-26%) at age 70 in BRCA2 carriers. The new model gave a better fit than the current default in BRCAPRO, the likelihood being 70 log units greater; in addition, the observed numbers of mutations in families stratified by gene and by cancer profile were not significantly different from those expected. Our new penetrance functions are appropriate for predicting breast cancer risk, and for determining the probability of carrying BRCA1/2 mutations, in people who are presently referred to genetic counseling in Italy. Our approach could lead to country-customized versions of the BRCAPRO software by providing appropriate population-specific estimates.
Introduction
Mutations in the two genes BRCA1 (MIM 113705) and BRCA2 (MIM 600185) account for 30-40% of the families with multiple breast cancer cases and for the vast majority of families with multiple breast and ovarian cancers cases. 1 -3 Taken together, these genes may be responsible for 5 -10% of early-onset breast cancers 4 -7 and about 10% of all ovarian cancers. 8 Estimates of cancer risks among mutation carriers provide valuable opportunities to tailor cancer screening and prevention strategies and to refine clinical and behavioral interventions to reduce cancer risk. 9 -12 Initial studies of multiple-case families with four or more cancer cases suggested that the lifetime risk of breast cancer in BRCA1 mutation carriers was 71 -85%, and that of ovarian cancer was 42 -63% at age 70. 13, 14 Similarly, earlypenetrance evaluations in BRCA2 led to an 84% risk of breast cancer and 27% for ovarian cancer at age 70. 2 Later studies, based on extensive typing of incident cases, have provided lower risks, 15 -17 for example, 40% penetrance of breast cancer at age 70 15 or 48% at age 80, 17 though with large sampling errors. A recent combined analysis of several previous studies 18 estimated the risk of breast cancer to be about 64% in BRCA1 and 39% in BRCA2 mutation carriers at age 70. Substantial uncertainty in the estimates remains.
Issues of variation across different populations and across different mutations of the same gene need to be investigated in further detail. 19 In the present work, we have addressed the question of estimating cancer-and gene-specific penetrances appropriate for the mutations segregating in a large sample of Italian multiple-case families screened for both genes. We used the software BRCAPRO, 20 ,21 a widely used program for predicting the presence of a germline mutation in a proband. Since the prediction made by this program is based on a specific genetic model (the set of parameter values, allele frequencies and penetrances that define the risk of disease in the population), it is possible to reverse the approach, that is, estimating some of the parameters from family data. This is accomplished by iteratively exploring new parameter values until the best genetic model is found, for which the prediction made by BRCAPRO is more accurate. In this approach, the likelihood of the genetic data (the observed test results) conditional on the phenotype is calculated. This is called the retrospective likelihood, and parameter estimates based on it remain unbiased even when the ascertainment method cannot be specified accurately, provided that ascertainment depends on phenotypes only. 22 While use of the retrospective likelihood has precedents, 2 our approach is novel in that it includes families negative at the genetic test, and accounts for test sensitivity.
Materials and methods
The families included in the present study have been described previously. 23 Figure 1 ); 15 mutations of BRCA1 and seven mutations of BRCA2 were identified more than once, with a maximum of nine families with BRCA1*5382insC and four families with BRCA2*6696delTC and BRCA2*IVS16-2A4G. These mutation frequency spectra are typical of large, non-isolated populations. In mutation analysis, three centers used both direct automatic sequencing and PTT-SSCP, one center used both PTT-SSCP and fluorescence-assisted mutational analysis (FAMA) and the last center used PTT-SSCP only. The program BRCAPRO computes the probability that a proband is a carrier of a mutation in either BRCA1 or BRCA2, based on the family history of breast and ovarian cancer in her first-and second-degree relatives and on published estimates of cancer-specific penetrances and mutated-allele population frequencies; model parameter files are regularly updated following published studies. 21, 24 BRCAPRO is also distributed as a part of the counseling package CaGene. 25 In the present context, BRCAPRO is used as a probability calculation tool to obtain new parameter estimates via a Metropolis -Hastings 26 MarkovChain Monte Carlo (MCMC) method. 27 The equations used to model the penetrance functions have the following form: where f g,j (x) is the incidence at age x for the carriers of a mutation in gene g (g ¼ 1 or 2 for BRCA1 and BRCA2, respectively) for cancer type j (j ¼ 1 or 2 for breast and ovarian cancer, respectively), f 0,j (x) are the corresponding incidences among non-carriers, and
Coefficients W 0 , W 1 , and W 2 are estimated. This form of the penetrance function allows for a parsimonious representation of the relationship between cancer, genotype and age. The density of cases in the general population, estimated Estimating penetrances from genetic test results F Marroni et al prevalence of mutation carriers is thus approximately 2(p 1 þ p 2 ). We assume uniform prior distributions on all parameters. At the kth iteration of the MCMC algorithm, a new set of parameters Ws and m is formed, based on the parameter values at the (kÀ1)th iteration and a proposal drawn from a multivariate t distribution, and the corresponding penetrance functions are calculated; the carrier probabilities are then determined by BRCAPRO for all the families in the study, and the total log likelihood of the new parameter set, given the observed test results, is calculated as
i g where the z i 's are indicator variables pointing to the carrier status of proband i (10 ¼ BRCA1, 01¼ BRCA2, 00¼ no mutation, 11 ¼ mutation in both genes), the p i 's are the corresponding carrier probabilities, and b is the sensitivity of the genetic test, set to 0.7. 21 In the families screened for one gene only, the log-likelihood function is modified by assuming that the determination of which gene to test is independent of genotype, as follows:
The proposed parameter set at each iteration k is accepted with probability ¼ 1 if L k 4L kÀ1 and with probability ¼ L k /L kÀ1 otherwise. Confidence intervals of parameters are obtained by examining their variation among the last 5000 iterations (after parameter values are stabilized); for each year of age, the values that excluded the 2.5% upper and lower tails of the penetrance distribution are taken as the 95% confidence intervals. In our retrospective likelihood approach, it is not possible to estimate allele frequencies for the two genes separately along with penetrance parameters Ws; therefore, the sum p ¼ p 1 þ p 2 was initially set to 0.003. 2, 14, 28, 29 Genespecific allele frequencies are not being estimated in this work, only their ratio. The entire analysis was also repeated considering the P-values 0.001, 0.002, 0.004 and 0.005. We first considered the full 'quadratic' model including three parameters for each of four penetrance functions plus the proportion m of BRCA1 vs BRCA2 mutation in the population (total parameters 13). To check if the model could be simplified without affecting the overall fit, we also used the 'linear' function Y(x) ¼ W 0 þ W 1 x in equation (1); this led to a reduction in the number of estimated parameters from 13 to 9.
Results
In all calculations, the sample stabilized in less than 2000 iterations, though the chains were continued for 10 000
iterations. Acceptance rate was near 40%. Considering the model with P fixed to 0.003, we obtained a final log likelihood, evaluated at point estimates, of about À326 for both the quadratic and the linear models, and the four resulting penetrance curves were practically indistinguishable. Therefore, we accepted the linear model. Repeating the analysis with lower values of P (0.001 and 0.002) had the effect of decreasing the equilibrium values of the log likelihood to about À345 and À331, respectively (19 and 5 log unit difference). On the other hand, increasing P to 0.004 and 0.005 caused a slight increase in log likelihood (À324 and À322, respectively); however, the penetrance curves associated to these values were still lower. For example, breast cancer risk for BRCA1 carriers at age 70 decreased from 39% (P ¼ 0.003, see Table 1 ) to 35% (P ¼ 0.004) to 34% (P ¼ 0.005). The four new penetrance curves of breast and ovarian cancer in BRCA1-2 mutation carriers corresponding to the model with p ¼ 0.003 are shown in Figure 2 , together with 95% confidence limits. Dotted lines show, as a reference, the default penetrance curves distributed with BRCAPRO, used in our previous study. 23 Breast cancer penetrance is lower, especially for BRCA1 carriers, whereas ovarian cancer penetrance in BRCA1 is higher (though the reference ovarian cancer penetrance curve is included in the 95% confidence limits of our estimate). The penetrance of ovarian cancer in BRCA2 is similar to the reference. Table 1 compares cancer penetrances at 50 and 70 years of age, as estimated by our model, to those of previous studies, whereas Table 2 shows the age-specific incidences at 10-year intervals in our estimates. Considering the frequency of the mutated alleles, the value of the parameter m was 0.57 (95% CI 0.44 -0.69), leading to an estimate of 3.4 Â 10 À3 for the prevalence of BRCA1 mutation carriers (B1:300 individuals) and 2.6 Â 10 À3 for that of BRCA2 mutation carriers (B1:400 individuals) in our sample. Lastly, we used the estimated penetrances as input in BRCAPRO to predict the presence of a mutation in probands in our sample. As those are the same samples used in training the model, this exercise is a goodness-of-fit evaluation rather than a validation. In our previous evaluation study, 23 it emerged that none of the currently available mutation-predicting models was able to accurately discriminate between the two genes, either because models did not address this (eg, Myriad Tables and Couch model) or because the discriminating ability was limited (BRCAPRO and IC models). However, difference in expressivity may be better exploited to distinguish between the two genes. 30 We investigated this issue by stratifying our families in the four typical profiles (HBC, HBOC, HOC, and MBC), and computing the observed and expected number of mutations separately for the two genes (Table 3) . While the estimated parameter values maximize the overall fit by construction, it is interesting to explore whether the come from MBC families (penetrance of MBC was not estimated in the present work). The last column in Table 3 shows the difference between the log likelihoods computed with the penetrance functions estimated in this work and the default penetrance functions in BRCAPRO; the highest increases concern the HBC families in BRCA2 and the HBOC families in BRCA1. HBC families were disproportionately assigned to BRCA1 by the previous predictions.
Discussion
Determining the appropriate values of cancer risks in women who carry a mutation in BRCA1 or BRCA2 is crucial for establishing the most appropriate preventive measures. However, estimation of penetrance is a difficult task, being subjected to different sources of bias; 31 considerable uncertainties remain about the 'true' values. A novel aspect of the present work is that it includes information from all tested families, both mutation-positive and mutationnegative; previously published estimates were based on information drawn from pedigrees of mutation carriers only. 2,16 -18 Our approach consisted in determining the penetrance curves that optimize the goodness-of-fit of a Mendelian model that predicts the presence of a mutation in a proband, given its personal and family cancer history. An advantage of this methodology is that it can be applied to family collections whose ascertainment scheme is loose. The most noticeable result of this work is that the breast cancer penetrance in BRCA1 carriers is lower than in previous studies. An important feature of our family data set is the high proportion of families with mild family history, which probably reflects the recent increase of genetic-test demand. From this point of view, our study sample may be considered intermediate between the multiple-case studies, based on highly selected families, and the population-based studies, in which typing is performed irrespective of family history of cancer; our penetrance estimates are more consistent with the latter studies. We have previously shown 23 that all extant predictive models underestimated the probability of identifying mutations in the families with calculated prior probability o10%. If a persistent excess of mutations is identified as far as more and more low-risk families are typed, this supports the idea that cancer penetrances of these mutations were previously considered too high. A complication in estimating a certain penetrance curve is that a single entity common to all populations may not exist; 32 each population has its own mutation spectrum, Table 1 Penetrances (with 95% CI) of breast and ovarian cancer in BRCA1-2 mutation carriers estimated in the present study (last row), compared to previously published estimates Estimating penetrances from genetic test results F Marroni et al with different prevalence of specific founder mutations, and different mutations may confer different breast and ovarian cancer risk. Consequently, each study estimates the average risk to carriers specifically for the population being studied. The population included in the present study is representative of the patient population that is referred for genetic testing for BRCA1 or BRCA2 mutations in Italy. Genetic counselors are interested in penetrance estimates relevant to the risks in the sort of families that are coming into counseling; thus, our estimated model is appropriate for use in determining the probability of carrying BRCA1/2 mutations in Italian families. We are implementing a version of BRCAPRO that can be distributed to genetic clinics in this country.
Another explanation for the finding of lower breast cancer risk accompanied by increased ovarian cancer risk in BRCA1 carriers could be the presence of a particular mutation spectrum in the study set, for example, if there was an unusually high proportion of mutations associated with early-onset ovarian cancer; however, this is not the case, as it was shown in our previous analysis of a similar data set, 30 and it is also apparent by inspection of Figure 1 .
However, this issue should be investigated in greater details, as there may be substantial allelic heterogeneity Estimating penetrances from genetic test results F Marroni et al in cancer risks in both BRCA1 and BRCA2. 16, 17, 33 This issue has received little attention until recently, as it requires collecting large samples of families sharing the same mutations. We are investigating this issue in our data. It is possible that at least some of the mutations identified in families at relatively low cancer risk contribute to lower the average penetrance in comparison with the previous estimates, which were necessarily based on highly selected families, that is, those possibly harboring mutations with a relatively stronger phenotypic effect. A disadvantage of the approach used here is that it is not possible to estimate simultaneously both the mutated allele frequencies and the penetrances in the same data set. Even in previous studies, either the prevalence of gene carriers assuming known penetrances were estimated, 4, 17 or the penetrances assuming known prevalence were estimated. 2, 13 We have chosen an initial value of 0.003
for the cumulative frequency of the mutated alleles based on an early segregation analysis study, 28 in which all the parameters of the genetic model (gene frequency and penetrances) can be independently estimated; this requires, however, that the ascertainment method is clearly defined. We have tried to address the robustness of our penetrance estimates by repeating the entire analysis with different values of the cumulative allele frequency. Values lower than 0.003 caused a decrease in the total log likelihood, whereas higher values caused a small increase in the log likelihood, accompanied by a further decline of the penetrances. Therefore, the genetic model with p ¼ 0.003 may represent a combination of values (allele frequencies and penetrances) that gives a good representation of reality, though for an ultimate answer we probably must wait until technology will allow estimating the allele frequencies by direct allele count in large random samples of the general population. A key element of the genetic counseling consultation is the identification of probands whose risk is higher than a certain threshold, such as to justify the genetic test. The ASCO has recently suggested that BRCA gene mutation screening should be limited to individuals whose probability for carrying a mutation is at least 10%. 25, 34 Applying this criterion to our new model, we find 338 probands with carrier probability 410% (59.5% of all families), among which 119 mutations in either gene were identified, or a mutation detection rate of 35.2%. On the other hand, 14 mutations (seven in each gene) have been identified in the 230 probands (40.5%) with probability o10%, or a mutation detection rate of 6.1%. Considering the default penetrance files distributed with BRCAPRO, 263 families (46.3% of total sample) had carrier probability 410%, in which 101 mutations were detected (whereas 32 mutations were found in the low-risk group). Therefore, the 10% probability threshold requires testing 75 more families in the new model (an increase of 13.2%), but the proportion of mutations identified in the low risk group is lowered from 24.1 to 10.5%. Thus, not only the old model classified a higher number of families at low risk, but also the proportion of mutations identified among them was higher. 
